modelB05XA05

Diagram of B05XA05

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:MagnesiumSulfate
ATC code:B05XA05
route:intravenous
compartments:2
dosage:4000mg
volume of distribution:13.65L
clearance:4.45L/h
other parameters in model implementation

Magnesium sulfate is an inorganic salt used in medicine for multiple applications, including the management of eclampsia and pre-eclampsia in obstetrics, as a tocolytic agent, for treating magnesium deficiency, and as an adjunct in severe asthma exacerbations. It is approved and widely used today, primarily by intravenous administration in clinical settings.

Pharmacokinetics

Pharmacokinetics reported in healthy adult volunteers, both male and female, after intravenous administration of magnesium sulfate.

References

  1. da Costa, TX, et al., & Oliveira, AG (2020). Population Pharmacokinetics of Magnesium Sulfate in Preeclampsia and Associated Factors. Drugs in R&D 20(3) 257–266. DOI:10.1007/s40268-020-00315-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32642964

  2. Brookfield, KF, et al., & Carvalho, B (2016). Pharmacokinetics and placental transfer of magnesium sulfate in pregnant women. American journal of obstetrics and gynecology 214(6) 737.e1–737.e7379. DOI:10.1016/j.ajog.2015.12.060 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26767791

  3. Rower, JE, et al., & Finkelstein, Y (2025). Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations. Journal of clinical pharmacology 65(6) 665–674. DOI:10.1002/jcph.6179 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39775569

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)